Firefly Neuroscience announces publications on EEG analytics

Firefly Neuroscience (AIFF) highlights two impactful studies that demonstrate the utility of advanced Resting Electroencephalograms and Cognitive EEG data analytics in drug development and neuropsychiatric care. Study 1: Advancing Neuropharmacology with Novartis’ MIJ821: Dose-Dependent EEG Changes: Administration of MIJ821 showed clear trends linking post-dose resting EEG activity to dosage, supporting its role as a distal target engagement biomarker. Validation of EEG as a PK-PD Tool: EEG revealed changes consistent with ketamine’s known effects, including increased gamma power and decreased alpha power, potentially reflecting enhanced cognitive processing and sensory integration. Study 2: Objective Cognitive Assessments in Major Depressive Disorder Treatment: BNA Metrics as Cognitive Biomarkers: Baseline brain activation latencies, as measured through Firefly’s BNA technology, were longer in MDD patients compared to controls, but normalized post-treatment, reflecting improved cognitive functioning independent of antidepressant effects. Personalized Psychiatry: Firefly’s BNA pipeline for automatic EEG analysis offers a scalable solution for evaluating treatment efficacy, addressing both cognitive and emotional health in MDD patients.